Meet Mirvie

A team dedicated to shaping the future of pregnancy health

Meet Mirvie

A team dedicated to shaping the future of pregnancy health

Meet Mirvie

A team dedicated to shaping the future of pregnancy health

About Mirvie

Mirvie is shaping the future of pregnancy health by providing women and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.

1 in 5 pregnancies is impacted by complications that lead to lifelong health consequences for mom and baby. The proprietary Mirvie RNA platform uses a simple blood test to reveal vital information about a pregnancy’s unique biology and detect complications months before they occur.

The idea for Mirvie was sparked by the personal experience of one of the founders whose daughter was born prematurely.

 

Meet Mirvie’s world-class team of scientists and entrepreneurs

Mirvie’s team have brought to market category-first, non-invasive tests in both women’s health and in early cancer detection, used by millions today.

Michal Elovitz, M.D.

Chief Medical Advisor

Hong Frank

Head of Software Engineering

Carrie Haverty

Head of Product Management

Maneesh Jain

Chief Executive Officer
& Co-Founder

Naomi Kelman

Board Member

Karen Kirk

Vice President of Finance & Administration

Stanley Lapidus

Board Chair

Manfred Lee

Chief Operating Officer

Eugeni Namsaraev

Senior Vice President of Research & Development

Stephen Quake

Scientific Advisory Board Chair & Co-Founder

Morten Rasmussen

Head of Research

Investors

Mirvie has raised more than $30 million in early-stage financing from top-tier investors.

Interested in helping us shape the future of pregnancy health?

Then we want to hear from you! Contact us using our contact form or review our careers page to see our current openings.